Goldman says buy this under-the-radar stock

Goldman Says Buy this Under-the-Radar Stock Expected to Rally

Morsa Images | DigitalVision | Getty Images

This little-known California-based biopharmaceutical stock can see its shares rally nearly 80% in the near term, according to Goldman Sachs.

Shares of the company's stock were up more than 5% in trading Thursday on the back of Goldman analyst Paul Choi who issued a buy rating for this stock.

Subscribe to CNBC Pro to see which stock Goldman is predicting could rally nearly 80%.

See the Stock

Here are more of today's top stories, exclusively for CNBC Pro subscribers!

Chip stocks have had a tough year — but one looks 'really inviting,' fund manager says

THU, OCTOBER 20 2022

Here are Thursday's biggest analyst calls: Apple, Tesla, Amazon, Dick's, Sunrun, Nike & more

THU, OCTOBER 20 2022

Too cheap? 18 stocks with single-digit P/Es that are expected to rally

THU, OCTOBER 20 2022

Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%

THU, OCTOBER 20 2022

Bernstein says Musk was 'curt' and 'almost dismissive' on earnings call, sees stock dropping nearly 30%

THU, OCTOBER 20 2022

Should you trust this recent market rally? Here's how Wall Street is advising their clients

THU, OCTOBER 20 2022

Like getting these emails? Subscribe to CNBC Pro today and get access to unlimited Pro articles, access to Pro live events, stock tips, and money-making investment ideas.